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Herpes simplex virus type 1 (HSV1), when present in brain of carriers of the type 4
allele of the apolipoprotein E gene (APOE), has been implicated as a major factor in
Alzheimer’s disease (AD). It is proposed that virus is normally latent in many elderly
brains but reactivates periodically (as in the peripheral nervous system) under certain
conditions, for example stress, immunosuppression, and peripheral infection, causing
cumulative damage and eventually development of AD. Diverse approaches have provided
data that explicitly support, directly or indirectly, these concepts. Several have confirmed
HSV1 DNA presence in human brains, and the HSV1-APOE-ε4 association in AD. Further,
studies on HSV1-infected APOE-transgenic mice have shown that APOE-e4 animals display
a greater potential for viral damage. Reactivated HSV1 can cause direct and inflammatory
damage, probably involving increased formation of beta amyloid (Aβ) and of AD-like tau
(P-tau)—changes found to occur in HSV1-infected cell cultures. Implicating HSV1 further in
AD is the discovery that HSV1 DNA is specifically localized in amyloid plaques in AD. Other
relevant, harmful effects of infection include the following: dynamic interactions between
HSV1 and amyloid precursor protein (APP), which would affect both viral and APP transport;
induction of toll-like receptors (TLRs) in HSV1-infected astrocyte cultures, which has been
linked to the likely effects of reactivation of the virus in brain. Several epidemiological
studies have shown, using serological data, an association between systemic infections
and cognitive decline, with HSV1 particularly implicated. Genetic studies too have linked
various pathways in AD with those occurring on HSV1 infection. In relation to the
potential usage of antivirals to treat AD patients, acyclovir (ACV) is effective in reducing
HSV1-induced AD-like changes in cell cultures, and valacyclovir, the bioactive form of ACV,
might be most effective if combined with an antiviral that acts by a different mechanism,
such as intravenous immunoglobulin (IVIG).
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INTRODUCTION
The concept of a viral role in Alzheimer’s disease (AD), specifically
of herpes simplex virus type 1 (HSV1), was first proposed several
decades ago (Ball, 1982; Gannicliffe et al., 1986). Legitimizing
the concept clearly depended on a positive answer to a number
of test questions, the first of which was whether or not HSV1
is ever present in human brain. The subsequent discovery that
HSV1 DNA resides in a high proportion of brains of elderly
people in latent form (Jamieson et al., 1991)—both normals and
AD patients—immediately made the concept more credible, but
raised associated questions such as whether or not the virus is ever
active in brain or is merely a passive resident there; whether on its
own it is a causative factor in AD or it acts thus only with another
factor, perhaps genetic; if active, what causes its activity; whether
there is any link with the characteristic abnormal features of AD
brains or their components, and whether, if indeed implicated
in AD, antiviral agents would be useful for treating the disease.
These questions were posed in a previous review (Wozniak and
Itzhaki, 2010)—and strong evidence was presented that permitted
the answer to each question to be “yes” or, very likely to be “yes”.
The present review briefly summarizes the earlier evidence, and
provides an update, which is especially timely in view of the
subsequent steady increase in number of relevant publications.
In contrast to the high frequency of HSV1 DNA in elderly
brains, the viral DNA was found to be present in only a very small
proportion of brains of young people and children (Wozniak
et al., 2005, 2009). It was therefore suggested that HSV1 enters
the brain in older age, as a consequence of the decline in the
immune system with age. Subsequently it was found that the virus
in brain of carriers of the APOE-e4 allele confers a strong risk
factor for AD (Itzhaki et al., 1997), accounting for some 60%
of cases. Further, evidence was obtained indicating that HSV1
reactivates in brain and causes a productive infection, perhaps
recurrently (Wozniak et al., 2005). Active HSV1 infection causes
severe damage and usually leads to cell death. It was therefore
suggested that HSV1 might periodically reactivate in brain during
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episodes of stress, immunosuppression or inflammation, causing
cumulative—though necessarily limited and localized) damage—
which is greater in APOE-e4 carriers, leading eventually to the
development of AD. Reactivation events have long been known
to occur in the peripheral nervous system, where HSV1 resides
lifelong in the trigeminal ganglia; they cause overt damage in
the form of cold sores (herpes labialis) in some 20–40% of
those infected, whereas others remain asymptomatic—an enigma
solved by work in the author’s laboratory (Itzhaki et al., 1997, and
see below), and subsequently confirmed by another (Koelle et al.,
2010).
HSV1 effects are both direct—including subverting the cell’s
machinery to produce viral instead of cellular components, and
indirect, via inflammatory processes. The neuropathological pro-
cesses leading to the disease—which is generally acknowledged to
be multifactorial—are unknown. However, in the case of HSV1
acting with APOE-e4, they might occur via the virus’s known abil-
ity to cause accumulation of beta amyloid (Aβ), and AD-like tau
(P-tau), the main components respectively of the characteristic
amyloid plaques and neurofibrillary tangles (NFT) of AD brains
(see Itzhaki and Wozniak, 2012). Several studies add support to
the above scheme: firstly, APOE has been found to modulate
severity of disease (or susceptibility to infection) in the case of
several diseases of microbial cause, including two caused by HSV1
and herpes simplex virus type 2 (HSV2)—namely, herpes labialis
(Itzhaki et al., 1997) and genital herpes (Jayasuriya et al., 2008).
For both of these, APOE-e4 is a risk factor, paralleling its proposed
role as a risk for AD in the CNS; secondly, HSV1 DNA is located
very specifically within the characteristic amyloid plaques in AD
brains (Wozniak et al., 2009).
Reactivation of HSV1 in brain obviously does not lead to overt
herpes simplex encephalitis (HSE), as that outcome would be
probably be fatal unless diagnosed rapidly and treated imme-
diately with antivirals. Therefore reactivation events must pre-
sumably be very localized or mild; in fact such limited and
asymptomatic reactivations have been described in a number of
cases of recurrent HSE (see below).
Consistent with the concept of a viral role in AD, at least
two other viruses, measles and human immunodeficiency virus
(HIV), can cause changes in brain similar to those characteristic
of AD. Measles virus, years after the initial infection, can lead to a
rare but very severe disease, subacute sclerosing panencephalitis,
in which NFT appear in brain (Wisniewski et al., 1979), and HIV
infection leads to the formation of AD-like tau (Anthony et al.,
2006). Also, postencephalitic parkinsonism, which is thought to
be caused by a virus, is characterized by NFT (Buée-Scherrer et al.,
1997).
In the last 23 years, many studies have been published—some
37 of these by groups other than the author’s—using diverse
approaches and yielding diverse types of information, all of which
explicitly support, or are consistent with, the proposed role for
HSV1 in AD. In contrast, there have been very few publica-
tions describing contradictory data. Both sets of studies will be
described below, though briefly in the case of those that were
cited in two previous reviews (Wozniak and Itzhaki, 2010; Itzhaki
and Wozniak, 2012), but it is worth mentioning that despite the
preponderance of supportive data, the concept of a viral role
in the disease is still regarded by some as controversial. This is
probably because certain aspects relating to virus “behavior”—
or indeed of microbial behavior—are either not understood, not
considered, or not even recognized, by some researchers in the
field. Indeed, there is a long history of resistance to the concept
of microbial involvement in certain chronic diseases, even when
incontrovertible experimental evidence had been obtained (as, for
example, when Peyton Rous discovered a cancer-producing virus
(Dulbecco, 1976)).
The first of the two aspects of microbial action that needs to be
recognized is that microbes can cause not only acute infections—
acting as hit-and-run agents—flying in, causing damage, and
then flying out of the body: they can cause chronic diseases
too. In fact certain microbes can remain in the body lifelong,
mainly in a dormant state but occasionally or eventually becom-
ing activated, and they then cause damage, sometimes severe or
even fatal, to their host. The second aspect is that response to a
microbe—susceptibility to infection, and/or the extent of damage
caused if infection ensues—can differ from person to person,
determined by genetic factors or immune responses. Thus, the
outcome can range from uninfected, to asymptomatic infection,
to severe or fatal illness, with the likelihood that an asymptomatic
person would be classed as a “control”, despite harboring the
microbe. Indeed, in some diseases, the proportions of those
infected in the patient and control groups are very similar. In
other words, “infect” does not necessarily mean “affect”. Some
of those researchers who object to a viral role invoke the first
of Koch’s postulates—that the microorganism must be found in
abundance in all organisms suffering from the disease, but not
be found in healthy organisms—as an argument against these
concepts. However, Koch himself realized that this postulate was
invalidated by the fact that some microbes can cause asymp-
tomatic infection. In any case, if the postulates are applied to
viruses, they need to be modified in several respects, as viruses
are not independent organisms but instead multiply only within
cells.
This review deals not only with updates on topics that
were covered in the author’s most recent review, but also
with topics not covered previously, namely, the possibility that
cytomegalovirus (CMV) rather than HSV1 is a cause of AD; epi-
demiological studies on HSV/HSV1-specific humoral responses;
genetic studies; evidence of reactivation of HSV1 in the CNS;
effects of infection of mouse brains on Aβ and P-tau; studies on
HSV1-infected cell cultures; and the case for antiviral treatment
for AD patients.
IS CMV RATHER THAN HSV1 A CAUSE OF AD?
The possibility that CMV, another member of the herpes family
of viruses, rather than HSV1 is a major factor in AD has been
considered in a number of publications. This is based on the many
studies that have implicated the virus in immunosenescence,
although it should be said that its role in the latter is unexplained,
and many aspects are controversial. However, what is presumably
the most obvious requirement—the presence of CMV in brain
of AD patients—has not been established. In contrast, HSV1
DNA has been found in human brain by seven independent
groups, including the author’s, the latter using three different
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methods: solution and in situ PCR, and immunological (Of the
sole contradictory studies, two detected HSV1 DNA in only a very
small percentage of subjects, and the third showed only a trend for
HSV1-APOE-ε4 association conferring a risk of AD; these and the
HSV1-positive findings were reviewed by Wozniak and Itzhaki,
2010). A further general point should be considered (Itzhaki et al.,
1997)—that brains cannot be described truly as virus-negative
when based on analyses of necessarily small specimens of the
1.5 kg organ.
The first study to seek CMV (Taylor and Crow, 1986) used the
pre-PCR technique of DNA hybridisation, at a stated detection
limit of one viral genome per 50 cells. However, neither CMV
nor HSV1 was found in normal or AD brains. The only other
study, in the author’s laboratory, sought CMV DNA by PCR,
and detected it in 36% of AD brains and 35% of age-matched
controls (Lin et al., 2002a). However, it was stressed that the
value might be artefactually high, as no account could be taken
of virus residing in lymphocytes within blood vessels rather
than in brain cells (Interestingly, CMV DNA was detected in a
much higher proportion—93%—of brains from vascular demen-
tia patients (Lin et al., 2002b)). In fact although CMV can cause
encephalitis, the latter is extremely rare in the immunocompetent,
occurring only in those with severe T-cell-mediated immune
deficiency.
The other approach to investigating the possible role of CMV
in AD has involved examining serum antibody titres to the virus,
as well as to other viruses and bacteria, and seeking to relate the
titres to the occurrence of AD and/or to changes in cognition.
Again, the most comprehensive early study (Renvoize et al., 1987)
gave negative results for adenovirus, chlamydia Group B, Coxiella
burnettii, HSV, influenza A, influenza B, measles and Mycoplasma
pneumoniae), as well as CMV, in that the titres were similar in
AD patients and controls for each pathogen. However, a more
recent study, with presumably greater sensitivity, by Strandberg
et al. (2003) discovered that viral burden—seropositivity for
HSVI, HSV2, or CMV—was associated with cognitive impair-
ment among home-dwelling elderly individuals with vascular
disease (mainly coronary heart disease), although no significant
associations were observed between bacterial burden (chlamydia
pneumoniae (Cpn) and mycoplasma pneumoniae) and cognition.
Later, Strandberg et al. (2005) found maximally increased risk
of cognitive impairment, in elderly home-dwellers, in association
with a combination of three factors: seropositivity for herpesviri-
dae, presence of APOE-ε4, and low education, the data indicating
that not only APOE-ε4, but also the epsilon3 haplotype, is a risk
factor for dementia.
Katan et al. (2013) similarly investigated infectious burden
(IB) in multiethnic elderly subjects with vascular risk, measuring
IgG levels for Helicobacter pylori, HSV1 and HSV2 and IgA for
Cpn, and cognition by Mini-Mental State Examination (MMSE),
at enrollment and on annual telephone interview. Higher IB
was found to be associated with worse cognition. The authors,
like Strandberg et al., concluded that most of the effects of
IB on cognition were mediated by viral rather than bacterial
burden. However, they found no APOE effect on IB in respect
to cognition. Another study, by Tarter et al. (2014), examined
CMV and HSV1 seropositivity over a range of age groups in
the general population. They found that HSV1 seropositivity in
children was associated with impaired cognition, in the middle-
aged with impaired reading and visuospatial processing and
slower coding speed, and among older adults with immediate
memory impairment. In contrast, CMV seropositivity was asso-
ciated only with slower coding speed and impaired learning and
recall in the middle-aged. They therefore suggested that HSV1
might have a life-course effect on cognition, while CMV effects
might be restricted just to the middle-aged. As the age of pri-
mary infection with herpesviruses is affected by socio-economic
factors—rising with increasing levels of the latter—the authors
pointed out that these pathogens might contribute lifelong to
“social disparities in cognition, educational attainment and social
mobility”.
Westman et al. (2014) examined in AD patients and non-
demented controls the functional capacity and cytokine release
profile of peripheral blood mononuclear cells (PBMCs) in
response to CMV and Aβ antigen challenge, and APOE geno-
type and systemic inflammatory biomarkers. Their data, and
the evidence from other studies that HSV-1 resides in brain of
AD patients, plus the epidemiological links to negative cognitive
effects at all ages (Tarter et al., 2014), led them to propose that
CMV deregulates inflammatory responses; it could thereby cause
frequent or prolonged HSV-1 reactivation, increasing the risk of
AD. An alternative mechanism was that CMV infection might
directly affect AD pathogenesis by increasing local inflammatory
response to various antigens, possibly including Aβ, increasing
amyloid precursor protein (APP) production and formation of
toxic amyloid protofibrils, leading to cognitive decline. In either
case, CMV was posited as an inflammatory promoter in AD
immunology. As the authors mention, this conclusion was con-
sistent with the results of Stowe et al. (2012). The latter showed,
in a very informative study of 1454 multiethnic subjects aged
25–91, that high antibody titres to HSV1—presumably reflect-
ing high reactivation rates—were significantly associated with
both CMV seropositivity and with high CMV antibody levels;
also, increases in HSV1 antibody level with age occurred in
CMV-seropositive people—just in those with low CMV antibody
levels, since individuals with high levels already had high HSV1-
antibody levels, but did not occur in people who were CMV-
seronegative. Stowe et al. concluded that CMV can influence
immune response to other pathogens, and might trigger the
immune dysregulation involved in some age-related diseases, and
they suggested specifically that HSV1 reactivation is associated
with CMV and age.
Lurain et al. (2013) analyzed serum and cerebrospinal (CSF)
fluid for associations between CMV infection and AD. They
found that CMV-specific serum IgG antibody levels were asso-
ciated with NFT of AD brain, as, also, was CSF interferon γ,
which was detected only in CMV-seropositive patients; also, the
percentage of senescent T cells was significantly higher in CMV-
seropositive than in seronegative patients. Although the authors
considered that CMV rather than HSV1 was implicated in AD
(but see comment by Itzhaki and Klapper, 2014), their data were
wholly consistent with the concept that inflammation caused by
infections can affect the brain, resulting in reactivation of HSV1
resident in the CNS.
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EPIDEMIOLOGICAL STUDIES ON HSV/HSV1-SPECIFIC
HUMORAL RESPONSES
Several studies have sought anti-HSV1 IgM as well as IgG in
serum from AD patients, on the basis that the presence of IgM
is associated with recent reactivation of HSV1, in contrast to
IgG, which shows only that the person has been infected with
HSV1. It should be added though that serum antibody levels
reflect the response to the virus in the periphery; whether or
not it reflects also the response to virus in the CNS is uncertain.
However, it does seem likely that events that cause reactivation
in the periphery, such as stress and immunosuppresssion, would
cause reactivation also in the brain, but perhaps less frequently,
and certainly in brain they might be much more difficult to detect.
The first study on anti-HSV IgM, by Letenneur et al. (2008),
revealed that elderly subjects who were IgM-positive were far
more likely to develop dementia within the following 14 years
than were those who were IgG- but not IgM-positive, thus sup-
porting the concept that reactivation of the virus leads eventually
to dementia. Subsequently, Féart et al. (2011) found that high IgM
levels, but not IgG levels, are associated with low plasma levels of
Aβ1-40 and 1-42—which are considered to be biomarkers of the
disease, in that their decrease might reflect accumulation of Aβ
in brain cells (and hence a reduction in plasma level). Although
the authors considered that virus reactivation might occur as a
consequence of an initial accumulation of Aβ in brain rather
than being a cause of accumulation, nonetheless they concluded
that their data supported the involvement of virus reactivations
leading to alterations in APP processing, and eventually to AD.
No association of APOE-ε4 with IgM positivity was found in
either study, which the authors tentatively attributed to the small
number of people who were APOE-ε4 carriers and IgM-positive.
Alternatively, this could perhaps be explained, as in other cases in
which there apparently no APOE effect, if the latter determines
severity of damage caused by reactivation rather than occurrence
or frequency of reactivation (see e.g., Wozniak et al., 2005).
Lövheim et al. (2014) carried out a longitudinal prospective
cohort study, investigating a possible relationship between HSV
infection and AD by examining serum anti-HSV antibodies,
and several neuropsychological, social and professional features.
As the authors stress, the study was especially strong in that
the design was prospective, the number of participants large,
the follow-up duration lengthy, and the diagnostic evaluations
numerous. Their first cohort of 1000 people was recruited in
1998–1990 and these were followed every 5 years thereafter. Other
cohorts, each comprising around 1000 people, were recruited 5
years, 10 years and 15 years later, and in one case, participants
were followed every successive 5 years. The ages of the subjects
ranged from 35 years to 95 years. At all time points, a battery of
tests was used to assess participants’ memory systems, problem-
solving and decision-making ability, etc., and their health was
examined in detail. The results were consistent with those of
1HSV is the abbreviation used here when the method for detecting antibodies
was not specific for HSV1 or HSV2. However, it is very likely indeed that
the virus detected was in each case HSV1, as a far higher proportion of the
elderly have been infected with this virus compared to HSV2, and also, HSV2
encephalitis is extremely rare in adults.
Letenneur et al. (2008) and Féart et al. (2011), in revealing
that the presence of anti-HSV IgM antibodies—indicating HSV
reactivation—but not the presence of IgG antibodies, almost
doubled the risk of AD.
Another HSV antibody study, by Kobayashi et al. (2013),
investigated the IgG avidity index (AI) in relation to cognitive
function in AD and in amnestic mild cognitive impairment
(aMCI). The avidity is defined as the strength with which IgG
attaches to antigen, IgG avidity maturing with length of time
following primary infection: thus, IgG produced within the first
few months after primary infection exhibits low avidity, whereas
IgG produced several months or years later exhibits high avidity;
therefore the avidity can distinguish primary infection from past,
long-lasting or recurrent infection. The authors took AI as an
indicator of HSV1 reactivation, and scored patients’ MMSE and
frontal assessment battery. They found that those with aMCI
had a higher AI than healthy controls and, surprisingly, higher
than AD patients, suggesting that more frequent reactivation
occurs in the aMCI group. Also, the anti-HSV1 IgG AI and IgG
antibody titre differed between the controls and the aMCI groups,
indicating that HSV1 is involved in the change from a healthy state
to the onset of aMCI. The apparently lower reactivation rate in AD
might be explained by the occurrence of structural and functional
changes in brain caused by HSV1 (or other agents/factors), at
some time before the onset of confirmed AD.
An intriguing variant of HSV antibody studies, by Mancuso
et al. (2014), examined serum anti-HSV1 IgG titres of patients
with mild AD, and cortical gray matter volumes, measured by
MRI. As expected, IgG levels were similar for patients and age-
matched normal people. However, high antibody levels were sig-
nificantly more frequent in the patients, and correlated positively
with cortical bilateral temporal and orbito-frontal gray matter
volumes. To find if these features were specific for HSV1, similar
analyses were carried out for CMV antibodies. However, no such
correlation was found, strengthening the case for HSV1 involve-
ment. The authors commented that damage to the blood-brain
barrier (BBB) might enhance immune cell entry, and suggested
that HSV1-specific antibodies might play a protective role at early
stages of AD by reducing HSV1 activity in brain regions where the
BBB is disrupted.
GENETIC STUDIES
Several genome wide association studies (GWAS) have examined
genetic links between HSV1 and its host cells, generating complex
papers with particularly imaginative titles! Licastro et al. (2011)
reviewed recent data showing that a limited number of genes,
when combined, are strongly associated with AD, even though the
effect of any single gene or SNP was very weak (the OR values for
AD in every case being less than 2, apart from that of APOE).
They suggested that these genes might code for proteins that
interact in various processes, thus leading to a synergistic effect on
AD pathogenesis. Various possible mechanisms were considered,
including environmental agents triggering certain genes, which
might then affect other genes, thereby causing secondary effects
via apoptosis, immune responses, etc. The authors’ main propo-
sition was that microbes, in particular herpesviruses, might well
be the link for all SNP that GWAS has shown to be associated
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with AD: thus, the first set of genes found were located close to
the APOE locus, on chromosome 19; the second set were located
on different chromosomes, and an earlier study (Porcellini et al.,
2010) linked both sets, together with the PICALM gene, with sus-
ceptibility to herpes virus infection of the brain. A third set of five
such genes gave further support to the virus infection hypothesis,
through the genes potentially influencing one of the following
processes: virus transport to the brain, and circulation within
it, virus entry into neurons, regulation of defence mechanisms
against the virus such as the host immune responses, cell sensi-
tivity to apoptosis, or individual susceptibility to infection. They
concluded from these data, as well as experimental work on HSV1
and AD by others, and studies on SNPs in other genes involved
in various inflammatory responses—some of which have been
associated with viral infections—that “viruses of the herpes family
are among the most probable pathogen candidates (responsible
for) CNS neurodegeneration in old age”.
Carter (2013) commented that HSV1 binds to many cell
proteins, thereby modulating probably their expression, including
many encoded by susceptibility genes for various neurological
diseases, including AD. The interactome is estimated to be 1347
genes, in a currently estimated total protein-coding genes number
of about 25000. The close association between viral interac-
tomes and disease susceptibility genes suggests that there might
be multiple gene/environment interactions which would allow
pathogens to cause disease in genetically susceptible individuals.
Surprisingly, the author stressed the point that the seroprevalence
of HSV1 is much greater than that of the disease and so “has per-
haps militated against a primary causal involvement”, even though
he subsequently conceded that host and microbial genetics play
a key role in determining outcome of infection. He commented
also that even though viral detection, antiviral drugs and vaccina-
tion might affect the incidence of many diseases, host/pathogen
protein mimicry suggests that the effects of treatments might be
affected by autoimmune features.
EVIDENCE OF REACTIVATION OF HSV1 IN THE HUMAN CNS
A major problem in studying the role of HSV1 in AD is the
current lack of a method for detecting reactivation of the virus
particularly if, as postulated, it occurs on a limited scale or in very
localized regions of the CNS. Obviously, the gross damage caused
during HSE is far more readily detectable—nowadays by seeking
HSV1 DNA in the CSF, in which it remains for about a week after
the start of the outbreak. However, there have been a number
of case reports of HSE recurring some months or years after the
initial episode, and it has been suggested that there might be fairly
frequent occurrences of sub-clinical encephalitis which, because
of their mildness, might not be diagnosed correctly (Klapper et al.,
1984).
Interesting data were obtained by Peter and Sevall (2001) on
analyzing 3200 CSF specimens, from subjects of a wide range of
ages, sent to a reference laboratory for HSV testing. They found
that over-all, 26 were positive for HSV1 and 36 for HSV2, but
in the over-60 age group, the ratio of HSV-2–HSV-1 infection
was low, namely, 3:13, and 11 of the 13 HSV1-positive subjects
were female. In the over 70 s, comprising 1 male, 10 female,
10 were positive for HSV-1, with 1 female positive for HSV2.
Over all, there were almost twice as many HSV-1 and HSV-2
infections detected in females as in males. They commented that
their data display a particular bias for HSV1-CNS infection in
females aged over 70 years—an intriguing finding, in view of the
preponderance of females with AD.
A pre-PCR study on HSV1 in post mortem human brain spec-
imens strongly suggested that HSV1 reactivates there under con-
ditions such as immunosuppression (Saldanha et al., 1986). Brain
from patients with acute leukaemia, who had been immunosup-
pressed as part of their treatment, was examined by in situ hybridi-
sation using an 3H-HSV1 probe. Strong labeling, indicating the
presence of HSV1 DNA, was revealed in frontal and temporal
cortices of those who were HSV-seropositive but not in those who
were HSV-seronegative or who had not been immunosuppressed.
The incidental but salient point was made that in view of the
subsequent mandatory usage of antivirals to treat HSE, such an
investigation is unlikely ever to be carried out again.
Significantly, a review of multiple sclerosis patients treated
with natalizumab, which hinders inflammatory cell migration
into the CNS, revealed that between November 2004 and Decem-
ber 2012, 20 cases developed HSE (Fine et al., 2013), indicating
the presence—and reactivation—of HSV1 in the patients’ brains.
The authors commented that such treatment had in some cases
led to the patients developing progressive multifocal leucoen-
cephalopathy (caused by JC virus in brain, normally controlled
by the immune system); however, other CNS opportunistic infec-
tions had rarely been reported, so they urged greater awareness of
this risk.
EFFECTS OF HSV1 INFECTION OF MOUSE BRAINS RELATING
TO AD, INCLUDING EVIDENCE OF REACTIVATION
Martin et al. (2014) examined the CNS and trigeminal ganglia
of HSV1-infected mice for several markers of inflammation and
neurodegeneration, with the aim of finding evidence of asymp-
tomatic reactivation of HSV1. They detected viral ICP4 protein
not only during the acute, symptomatic phase of infection at
7 days but also at 60 days post-infection, well after the start of
the asymptomatic latent phase, thus indicating that reactivation
was occurring. Up-regulation of Interferon α and β and toll-like
receptors (TLRs) occurred concurrently, indicating neuroinflam-
matory action, consistent with their previous study showing that
HSV1 activates TLRs 2 and 4 in mouse astrocyte cultures (Villalba
et al., 2012), and that of Aravalli et al. (2005) in microglial
cells. Phospho-tau and caspase-3-cleaved tau, which indicate early
neurodegenerative processes, were up-regulated also. The authors
concluded that their data support the hypothesis that HSV1in
brain reactivates recurrently, thereby promoting neuroinflam-
mation by triggering TLRs activation, thus conferring a risk of
neurodegeneration.
The interaction of aging, HSV1 infection, gender and APOE in
mouse brains was investigated by Guzman-Sanchez et al. (2012),
who infected 2 month-old male and female wild-type and APOE-
knock-out mice, and studied them over the following 16 months.
Previous work by the same group (Burgos et al., 2003, 2006),
had shown that APOE determines the viral load in the CNS
during the acute and latent phases of infection, and was greater
in APOE-ε4-transgenic than in APOE-e3 animals; also the load
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in female brains was greater than in males. Their 2012 study
found that the viral load in brain was maximal during the acute
phase, declined during adulthood and then increased with ageing,
and that in wild-type female mice the load was 43 times greater
than in apoE-K/O animals. Surprisingly, there were no detectable
morphological or pathological differences between infected and
mock-infected old animals. However, infection caused a memory
deficit and reduced a metabolic measure of neuronal health. The
authors commented that their results might explain the data
indicating that the combination of HSV1 in brain and APOE-e4
carriage confers a strong risk of AD.
Sy et al. (2011) postulated that infections might promote
the development of AD by exacerbating pre-existing neuroin-
flammation, hence accelerating cognitive decline. They induced
inflammation in mouse brain by viral infection or lipopolysac-
charide (the latter mimicking bacterial infection), to find if the
inflammation modulated the AD-like features that develop in
aged triple-transgenic (3xTg-AD) mice. A single dose of mouse
hepatitis virus was used, thus causing an acute infection and a
strong neuroinflammatory response. It was found that immune
responses and mortality did not differ between the 3xTg-AD
and non-Tg mice. No accumulation of Aβ occurred, but tau
phosphorylation increased in the 3xTg-AD mice, though not in
the non-Tg animals, and it increased also at 2 and 4 weeks post-
injection, after the viral infection had been cleared, and when no
short-term immune responses remained. Also, at the later stage,
both groups of infected mice showed spatial memory impair-
ments and demyelination in the spinal cord. Repeated treatment
with LPS, which induced a sustained neuroinflammation, caused
these changes too. The authors suggested that similar effects of
infection might occur in human brain, thereby exacerbating tau
pathological features, and leading to AD.
COMPARISON OF AD BIOMARKERS AND OTHER AD
PROTEINS WITH PROTEINS OF KNOWN CNS INFECTIONS
A novel study by Krut et al. (2013) compared CSF biomarker
profiles of AD with various CNS infections, including HSE. Values
for AD and HSE, in contrast to the other infections (Lyme neu-
roborreliosis, bacterial meningitis and HIV-associated dementia
(HAD)) showed a markedly similar pattern in all but one respect:
Aβ1-42 levels were lower in AD and HSE than in healthy controls,
and those of total tau (t-tau) and hyper-phosphorylated tau
(P-tau) were higher in AD and HSE than in the controls, but
none of these values differed significantly between the AD and the
HSE patients. Levels of soluble APP, however, were significantly
lower in HSE than in AD. The authors therefore suggested that
the mechanisms underlying the disturbed Aβ metabolism in the
two disorders might differ, while the similarity of their P-tau
and t-tau values might indicate that HSV1, as well as causing
hyperphosphorylation of tau in cell cultures (see below), causes
it also in vivo.
An interesting overlap of HAD proteins and AD proteins was
discovered by Zhou et al. (2010), who analyzed total proteins
from frontal cortices of HAD and HIV non-demented patients:
90% of the proteins they identified had been reported previously
for several neurological diseases including AD (referred to by the
authors as a “non-viral” disease for comparison with HIV, despite
their citing several studies on AD viral aetiology!). Indeed, as they
pointed out, their data might help to elucidate the involvement of
any pathogen in “non-viral” neurodegeneration.
STUDIES ON HSV1-INFECTED CELL CULTURES
In the author’s two preceding reviews (Wozniak and Itzhaki, 2010;
Itzhaki and Wozniak, 2012), work from several laboratories was
described showing that HSV1 infection of cultured cells, includ-
ing human neural cells, causes a marked accumulation of intracel-
lular Aβ and P-tau. Also, Aβ deposits are formed in the brains of
HSV1-infected mice (Wozniak et al., 2007). These increases were
explained by increases in the relevant enzymes which, in the case
of BACE, occur by HSV1-induced PKR activation and consequent
phosphorylation of eIF2α (Ill-Raga et al., 2011). Further, infected
primary neuronal and astrocyte cultures show AD-like caspase-3
activation and tau cleavage (Lerchundi et al., 2011).
De Chiara et al. (2010) examined the effects of HSV1 infection
on processing of APP in human neuroblastoma cells and rat
cortical neurons. They found that HSV1 caused multiple types of
cleavage of APP, some of which were produced through the action
of α- and β-secretases and caspase-3-like enzymes—processes that
occur in the amyloidogenic pathway—leading to the formation
of several potentially neurotoxic fragments. They stressed that as
their cells were not transfected to over-express APP, their data
might well more closely simulate events occurring in vivo, and
they speculated that on repeated reactivation of the virus in brain,
such fragments might play a major role in the pathogenesis of AD.
Another type of approach relating HSV1 to APP was pioneered
by Bearer and colleagues. They studied HSV1 assembly and
transport, and discovered that APP is a component of isolated
HSV1 particles, about 1000 or more APP molecules being present
in each particle (Satpute-Krishnan et al., 2003). Whether or not
APP is present in the virus particles within cells or, instead, it
joins them during the isolation procedure, is unknown. The aim
of a more recent study (Cheng et al., 2011) was to investigate the
latter, and also to find whether the APP affects virus intracellular
transport, and the converse—whether APP transport is affected
by the virus. Results obtained using GFP-tagged virus showed
that APP and HSV1 co-localize and travel together within cells
and that the distribution of APP is abnormal in HSV1-infected
cells. In Bearer (2012), she points out that the nascent HSV1
profoundly alters cell membrane organization and anterograde
transport, processes which are essential for neuronal function and
survival, with particularly great impact in the case of chronic
infection.
WOULD ANTIVIRAL TREATMENT HELP AD PATIENTS?
The merits of several antiviral agents which differ in their mecha-
nisms of action have recently been investigated in the author’s lab-
oratory in respect to their ability to reduce HSV1-induced P-tau
and Aβ production. The most commonly used antiviral, acyclovir
(ACV), which is usually administered to HSE sufferers as the
pro-drug, valacyclovir (VCV), because of the much greater oral
bio-availability of the latter, is very effective and very safe. ACV
acts by interfering with the replication of HSV1 DNA; it targets
specifically cells that contain replicating HSV1 in that its action
requires phosphorylation by the viral thymidine kinase (TK), The
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monophosphate form of ACV is then further phosphorylated
by cellular kinases to the active triphosphate form, which has a
greater affinity for viral than for cellular DNA polymerase. Acyclo-
GTP is incorporated into viral DNA, causing chain termination.
We argued that ACV might inhibit the HSV1-induced accu-
mulation of Aβ and P-tau only if their formation were to depend
on viral DNA replication. In fact our results (Wozniak et al., 2011)
showed that ACV, and also, penciclovir and foscarnet, two other
agents that inhibit the viral DNA replication, did reduce Aβ and
P-tau accumulation (as well as HSV1, as expected), in HSV1-
infected Vero cell cultures. However, with all three antivirals, P-tau
accumulation was found to depend on HSV1 DNA replication,
whereas Aβ accumulation was not. The antiviral-induced decrease
in Aβwas instead attributed to the reduced number of new viruses
formed, hence reducing viral spread. Also, P-tau accumulation
was reducible to near zero whereas that of Aβ was reducible only
to a near-normal value. In fact the lesser Aβ reduction seems
desirable in view of the possibility that Aβ might function at
least initially as part of the innate immune system—and there
are preliminary data suggesting that it does indeed have antiviral
activity (Klapper et al., in preparation)—although eventually
becoming toxic when over-produced. In other words, treatment
should perhaps aim not to eliminate Aβ but instead to reduce it to
near-normal levels—an aim achieved by ACV.
In another study, ACV was compared with an antivi-
ral, BAY 57–1293, which targets a different stage of viral
DNA replication—the helicase-primase complex (Wozniak et al.,
2013a). We found that BAY 57–1293 is more efficient than ACV
in decreasing Aβ and P-tau formation as well as HSV1 replication,
in infected Vero cell cultures. Also, the size of the cell clusters
that form during infection were reduced much more efficiently by
BAY 57–1293 than by ACV. These data suggest that BAY 57–1293
would be more effective than ACV for treating AD.
The next antiviral examined was intravenous immunoglob-
ulin (IVIG). We reasoned that its apparently beneficial action
in AD patients might result from its antiviral action rather
than its anti-Aβ antibodies; also, antivirals that act on HSV1
at an infection stage before viral DNA replication might be
more effective in treating AD. IVIG seemed an appropriate
choice for study as it can neutralize extracellular virus and
also can help (in conjunction with lymphocytes) to destroy
cells acutely infected with HSV1. We found (Wozniak and
Itzhaki, 2013b) that IVIG was effective at reducing accu-
mulation of Aβ and P-tau, in infected Vero cell cultures,
and that it acts synergistically with ACV, suggesting that its
use in combination with ACV would be beneficial for treat-
ing AD.
Amongst the many studies on VCV action in vivo, one of
possible relevance to future clinical trials of the antiviral for AD
was conducted on rabbits latently infected with HSV1, assaying
the extent of asymptomatic shedding of HSV1 DNA that was
known to occur in the animals’ saliva and tears. Similar shedding
in saliva and tears occurs also in humans. The effects of VCV,
administered to rabbits at high doses (70–140 mg/kg), on the viral
DNA in tears were examined by comparing the DNA levels in
tears, collected once a day for 6 days pre-infection, and 10 days
post-infection (Kumar et al., 2010). It was found that the high
dose VCV treatment significantly reduced the copy number of the
viral DNA.
The results of Kumar et al. point to the possibility that the
progress of antiviral treatment of AD patients could be monitored
by assaying viral levels in tears, and presumably in saliva also—
thus using the levels as biomarkers. However, so far there has
been no clinical trial of antiviral treatment for AD patients, the
reason being that applications for funding have been refused by
grant-giving bodies and pharmaceutical companies (the latter
presumably because VCV is off-patent). Yet evidence for a role for
HSV1 in the disease is steadily increasing—and every other drug
tested has failed to produce the magic bullet that would target
disease progression. Thus AD remains an untreatable disease.
Interestingly, VCV has been found to alleviate cognitive
impairment in schizophrenia patients. A test-of-concept double-
blind placebo-controlled trial by Prasad et al. (2012), assessed the
effects of VCV on cognitive performance and psychopathology.
Of 24 HSV1-seropositive patients aged 18–50 years, 12 were given
2× 1.5 g VCV twice daily and 12 given placebo for 18 weeks,
in addition to antipsychotics. Results showed that VCV-treated
subjects improved in verbal and working memory and visual
object learning, compared with the placebo group. The authors
pointed out that although there is no proven causal association
of HSV1 with schizophrenia, their data indicate an association of
the virus with cognitive impairments, especially in schizophrenia.
This study, together with those referred to above by Strandberg
et al. (2003, 2005), Katan et al. (2013), and Tarter et al. (2014),
that indicate that viral burden, and especially HSV1, is associated
with decreased cognition, provide ammunition for the concept
that HSV1 is indeed responsible for cognitive decline in some AD
patients.
Very intriguingly, memantine, an N-methyl-D-aspartate
(NMDA) receptor antagonist used for treating AD, either on its
own or combined with acetylcholinesterase, has recently been
shown to have strong antiviral activity. The efficacy of memantine
in AD, as detailed in individual clinical trials, and meta-analyses,
was recently reviewed by Rive et al. (2013). They found that it
was particularly important in reducing agitation and aggression,
features which are very common and are usually associated with
early institutionalization and with causing especially great stress
to care-givers. The authors therefore concluded that memantine
provides a valuable treatment for AD. The antiviral action of
memantine, which was found not to involve NMDA receptors,
was discovered by Brison et al. (2014): the drug reduced the effects
in mice of infection with a human neurovirulent coronavirus
which causes encephalitis, and a mutant of which induces a
paralytic disease involving glutamate excitotoxicity. Brison et al.
found that memantine acted by interfering with replication of
the virus, thereby resembling other compounds derived from
adamantane that inhibit virus replication, such as amantidine,
and tromantadine, an anti-HSV antiviral. They therefore pro-
posed the use of memantine to treat certain neurological diseases
of possible viral cause, such as AD.
CONCLUSIONS
The evidence presented here for the presence of HSV1 in the
elderly human brain, for its reactivation there, its interference
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with cellular processes and its harmful effects on cognition, is
very strong. The evidence for its absence, or its lack of association
with APOE-ε4 in AD, was presented in three publications—10,
12 years and 15 years ago. There is therefore very good support
for HSV1 being a causal factor in AD. However, with human
diseases, for which cell or animal studies cannot provide wholly
relevant information, and for which no direct experiments can be
carried out in vivo, the only absolute proof of causation would
be successful prevention of the disease by vaccination against the
virus, or reduction of disease progression by antiviral treatment.
Vaccination would have to be given in early infancy because of
the very young age of primary infection, and those vaccinated
would have to be followed for six or seven decades thereafter—
an unrealistic possibility. This leaves antiviral treatment as a
desirable, safe and potentially effective alternative.
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